Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Active not recruiting 3Completed 2

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Mastectomy × 90 days × Clear all
NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
2,175 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
164 enrolled 19 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡